Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Method for improving therapy for autoimmune diseases such as rheumatoid arthritis

一种自身免疫疾病、处置方法的技术，应用在处置自身免疫疾病领域，能够解决尚未知晓组合关节炎治疗药副作用等问题

Inactive Publication Date: 2014-05-28
TOYAMA CHEM CO LTD
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, it is not yet known whether combining arthritis drugs will reduce the side effects of the individual drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for improving therapy for autoimmune diseases such as rheumatoid arthritis
  • Method for improving therapy for autoimmune diseases such as rheumatoid arthritis
  • Method for improving therapy for autoimmune diseases such as rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0078] Next, the present invention will be described with reference to test examples, but the present invention is not limited thereto.

[0079] As a test substance, iguratimod was used. As immunosuppressants, methotrexate and prednisolone are used.

Embodiment 1

[0132] Alamod (Toyama Chemical Industry) 2.5g, crystalline cellulose (Asahi Kasei Chemical: CEOLUS PH-101) 15.9g, carmellose calcium (Gotoku Pharmaceutical: ECG-505) 0.7g and hydroxypropyl cellulose Vegetable (Nippon Soda: HPC-L) 0.2 g was mixed in a mortar. Water is added thereto for kneading. The kneaded mixture was sieved through a 20-mesh sieve, and the sieved product was dried at 40° C. overnight, and then sieved through a 16-mesh sieve to obtain a granulated powder. To the obtained granulated powder, 0.7 g of carmellose calcium and 0.04 g of magnesium stearate (Merck & Co.: magnesium stearate) were added and mixed to obtain a powder for tableting. The obtained powder for tableting was compressed in a rotary tablet machine using a punch with a diameter of 8.0 mm to obtain round tablets (200 mg) each containing 25 mg of iguratimod.

Embodiment 2

[0134] Alamod (Toyama Chemical Industry) 2.5g, crystalline cellulose (Asahi Kasei Chemical: CEOLUS PH-101) 15.9g, croscarmellose sodium (Asahi Kasei Chemical: KI CCOLATE ND-200) 1.4g and hydroxy 0.2 g of propylcellulose (Nippon Soda: HPC-L) was mixed with a mortar. Water is added thereto for kneading. The kneaded mixture was sieved through a 20-mesh sieve, and the sieved product was dried at 40° C. overnight, and then sieved through a 16-mesh sieve to obtain a granulated powder. 0.04 g of magnesium stearate (Merck & Co.: magnesium stearate) was added to the obtained granulated powder to obtain a powder for tableting. The obtained powder for tableting was compressed in a rotary tablet machine using a punch with a diameter of 8.0 mm to obtain round tablets (200 mg) each containing 25 mg of iguratimod.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

In the present invention, a method using a combination of iguratimod or a salt thereof and one or more immunosuppressants is useful as a method for the treatment of autoimmune diseases, and with this method adverse effects are lessened. A pharmaceutical composition containing this combination is useful for the treatment of autoimmune diseases. This method and pharmaceutical composition are useful for the treatment of more severe autoimmune diseases.

Description

technical field [0001] The present invention relates to the combined use of iguratimod (N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]formamide ) or a salt thereof and an immunosuppressant to treat (eg, treat or prevent) an autoimmune disease. In addition, the present invention also relates to a pharmaceutical composition containing iguratimod or a salt thereof and an immunosuppressant, which is used for treatment such as treatment or prevention of autoimmune diseases. Background technique [0002] Chronic arthritis caused by connective tissue diseases represented by rheumatoid arthritis etc. which are autoimmune diseases, for example, causes dysfunction with progressive destruction of cartilage and / or bone destruction, and brings difficulties to daily life. come to have a big impact. Although the etiology of autoimmune diseases is unknown, they are thought to be caused by an excessive immune response to self-antigens. [0003] In this context, in the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K31/519A61K31/573A61K45/00A61P19/02A61P29/00A61P37/06C07D311/22
CPCC07D311/22A61K45/06A61K31/519A61K31/573A61K9/2054A61K31/352A61P19/02A61P29/00A61P37/00A61P37/02A61P37/06A61P37/08A61P39/00A61P43/00A61K2300/00A61K9/0053A61K9/20
Inventor 田中启一
Owner TOYAMA CHEM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com